Gilead shows its belief in its partner’s cancer treatment with a $7.8 billion buyout
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
